Zentralbl Gynakol 2005; 127(5): 308-313
DOI: 10.1055/s-2005-836865
Übersicht

© Georg Thieme Verlag Stuttgart · New York

Leitlinien für den Einsatz der GnRH-Agonisten zur Behandlung der Endometriose

Guidelines for the Use of GnRH-Analogues in the Treatment of EndometriosisK. W. Schweppe1
  • 1Frauenklinik der Ammerland Klinik GmbH, Akademisches Lehrkrankenhaus der Universität Göttingen
Further Information

Publication History

Publication Date:
29 September 2005 (online)

Zusammenfassung

GnRH-Analoga sind z. Z. die wirksamsten Substanzen zur Regression der Endometrioseimplantate und zur Reduktion der endometriosebedingten Beschwerden. Kombiniert mit einer Add-back-Medikation ist die Behandlung effektiv und nebenwirkungsarm. Die verschiedenen GnRH-Analoga, die auf dem Markt sind, unterscheiden sich nicht hinsichtlich ihrer Wirksamkeit, jedoch haben Depot-Präparationen die beste Compliance. Der gezielte Einsatz der Medikation praeoperativ, postoperativ oder anstatt einer Operation, hängt von der individuellen Situation der Patientin und von Lokalisation, Aktivität, Wachstumstyp und Schweregrad der Endometriose ab.

Abstract

Today GnRH-Analogues are the most effective substances for the regression of endometriosis and endometriosis related complaints. In combination with add-back medication the treatment is effective with only few tolerable side effects. The different types of GnRH-Analogues are equally effective, but depot preparation have the best compliance. The tailored application of GnRH-Analogues preoperatively, postoperatively or instead of surgery is dependent on the individual situation of the patient and dependent on the proliferative activity, localisation, type and stage of the disease.

Literatur

  • 1 Abbott J A, Hawe J, Clayton R D, Garry R. The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2-5 year follow up.  Hum Reprod. 2003;  18 1222-1227
  • 2 Barhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilisation.  Fertil Steril. 2002;  77 1148-1155
  • 3 Bianchi S, Busacca M, Agnoli B. et al . Effects of 3 months therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomised study.  Hum Reprod. 1999;  14 1335-1337
  • 4 Busacca M, Somigliana E, Bianchi S. et al . Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomised controlled trial.  Hum Reprod. 2001;  16 2399-2402
  • 5 Donnez J, Nisolle M, Gillerot S. et al . Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage.  Fertil Steril. 1994;  62 63-66
  • 6 Donnez J, Nisolle M, Smoes P. et al . Peritoneal endometriosis and “endometriotic” nodules of the rectovaginal septum are two different entities.  Fertil Steril. 1996;  66 362-368
  • 7 Ebert A D, Bartley J, David S. et al . Aromatasehemmer - theoretisches Konzept und bisherige Erfahrungen in der Endometriosetherapie.  Zentralbl Gynäkol. 2003;  125 243-246
  • 8 Evers J L. The second-look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression.  Fertil Steril. 1987;  47 502-504
  • 9 Freundl G, Gödtke K, Gnoth C. et al . Steroidal ‘add-back’ therapy in patients treated with GnRH agonists.  Gynaecol Obstet Invest. 1998;  45 22-30
  • 10 Hemmings R. Combined treatment of endometriosis. GnRH agonists and laparoscopic surgery.  J Reprod Med. 1998;  43 316-320
  • 11 Hippach M, Hinrichs I, Schweppe K W. Möglichkeiten der Langzeittherapie bei rezidivierender Endometriose.  Zentralbl Gynäkol. 2003;  125 303
  • 12 Hornstein M D, Yuzpe A A, Burry K A. et al . Prospective randomised double-blind trial of 3 versus 6 months of narfarelin therapy for endometriosis associated pelvic pain.  Fertil Steril. 1995;  63 955-962
  • 13 Hornstein M D, Hemmings R, Yuzpe A A. et al . Use of narfarelin versus placebo after reductive laparoscopic surgery for endometriosis.  Fertil Steril. 1997;  68 860-864
  • 14 Hughes E, Fedorkow D, Collins J. et al .Ovulation suppression for endometriosis (Cochrane Review). In: The Cochrane Library, Issue 3. John Wiley & Sons Ltd, Chichester, UK 2004
  • 15 Irahara M, Uemura H, Yasui T. et al . Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis.  Gynaecol Obstet Invest. 2001;  52 217-222
  • 16 Jansen R P, Russell P. Nonpigmented endometriosis: clinical, laparoscopic, and pathologic definition.  Am J Obstet Gynecol. 1986;  155 1154-1159
  • 17 Kampe D, Sahl A C, Schweppe K W. Prä- und postoperative Endometriosetherapie mit GnRH-Agonisten in Depotform: drei- versus sechsmonatige Behandlungsdauer.  Zentralbl Gynäkol. 2003;  125 304
  • 18 Kennedy S, Bergqvist A, Chapron C. et al . ESHRE guideline for the diagnosis and treatment of endometriosis.  Hum Reprod.. 2005;  in press
  • 19 Kiesel L, Schweppe K-W, Sillem M. et al . Should add-back therapy for endometriosis be deferred for optimal results?.  Br J Obst Gynaecol. 1996;  103 15-17
  • 20 Lee P A, Houk C P. Outcome among adult females after treatment of central precocious puberty (CPP) with GnRH analogue (GnRH-A). 8th International Symposium on GnRH-Analogues 2005; abstract 68
  • 21 Malik E, Berg C, Meyhöfer-Malik A. et al . Fluorescence diagnosis of endometriosis using 5-aminolevulinic acid.  Surg Endosc. 2000;  4 452-455
  • 22 Malinak L R. Surgical treatment and adjunct therapy of endometriosis.  Int J Gynaecol Obstet. 1993;  40 S 43-S 47
  • 23 Marcoux S, Maheux R, Berube S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis.  N Engl J Med. 1997;  337 217-222
  • 24 Meldrun D R, Chang R J, Lu J. et al . Medical oophorectomy using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis.  J Clin Endocrinol Metab. 1982;  54 1081-1083
  • 25 Mori H, Taketani Y, Uemura T. et al . Rates of endometriosis recurrence and pregnancy 1 year after treatment with intranasal buserelin acetate (Suprecur) (a prospective study).  J Obst Gynaecol Res. 1999;  25 153-164
  • 26 Muzii L, Marana R, Caruana P. et al . The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts.  Fertil Steril. 1996;  65 1235-1237
  • 27 Muzii L, Marana R, Caruana P. et al . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomised trial.  Am J Obstet Gynecol. 2000;  183 588-592
  • 28 Parazzini F. Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomised trial. Gruppo Italiano per lo Studio dell' Endometriosi.  Hum Reprod. 1999;  14 1332-1334
  • 29 Prentice A, Deary A J, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. In: The Cochrane Library, Issue 3. John Wiley & Sons Ltd, Chichester 2003
  • 30 Radwanska E. The effect of GnRH Agonist suppression on the outcome of infertility treatment in women with endometriosis. 5th International Symposium on GnRH Analogues: Geneva 1999; abstract 86
  • 31 Regidor P A, Regidor M, Ruwe B. et al . Prospective randomised study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.  Gynecol Endocrinol. 2001;  15 202-209
  • 32 Regidor P A, Wagner I, Ruwe M. et al . Morphometric analyses of endometriotic tissues to determine their grade of activity.  Gynecol Endocrinol. 2002;  16 235-243
  • 33 Regidor P A. GnRH-Agonists and endometriosis: comparison of nasal spray and depot formulations. 8th International Symposium on GnRH-Analogues 2005; abstract 60
  • 34 Rickes D, Nickel I, Kropf S. et al . Increased pregnancy rates after ultra long postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis.  Fertil Steril. 2002;  78 757-762
  • 35 Rickes D, Weiß M, Nickel I. et al . Ovarielle Ansprechbarkeit auf rekombinante Gonadotropine nach ultralanger „Dornregulation” mit GnRH-Analoga.  Zentralbl Gynäkol. 2003;  125 306
  • 36 Ruwe M, Donhuijsen K, Regidor P A. et al . Endometriose: Klinische, histologische und morphometrische Befunde vor und nach Gn-RH-Agonisten-Therapie.  Zentralbl Gynäkol. 1998;  120 391-398
  • 37 Schindler A E, Förtig P, Kienle E. et al . Early treatment of endometriosis with GnRH-agonists: impact on time to recurrence.  Europ J Obst Gynec Reprod Biol. 2000;  93 123-125
  • 38 Schweppe K-W. Klinik und Morphologie der Endometriose. Schattauer Verlag, Stuttgart, New York 1984
  • 39 Schweppe K-W. Aktive - inaktive Endometriose - eine prognose- und therapierelevante Differentialdiagnose.  Zentralbl Gynäkol. 1999;  121 330-335
  • 40 Schweppe K-W, Ring D. Peritoneal defects and the development of endometriosis in relation to the timing of endoscopic surgery during the menstrual cycle.  Fertil Steril. 2002;  78 763-766
  • 41 Schweppe K-W. The use of GnRH analogues before and after surgery for endometriosis - clinical problems and experiences. 8th International Symposium on GnRH-Analogues 2005; abstract 37
  • 42 Shaw R W. The role of GnRH analogues in the treatment of endometriosis.  Br J Obst Gynaecol. 1992;  99 9-12
  • 43 Surrey E S, Hornstein M D. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long term follow up.  Obstet Gynecol. 2002;  99 709-719
  • 44 Surrey E S, Silverberg K M, Surrey M W. et al . Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilisation-embryo transfer in patients with endometriosis.  Fertil Steril. 2002;  78 699-704
  • 45 Sutton C JG, Ewen S P, Whitelaw N. Prospective, randomised, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild and moderate endometriosis.  Fertil Steril. 1994;  62 696-700
  • 46 Templeton A, Morris J K, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment.  Lancet. 1996;  348 1402-1406
  • 47 Tinneberg H-R, Manolopoulos K. Reproductive medicine: comparison of depot formulations of GnRH-Agonists, daily injections and nasal spray. 8th International Symposium on GnRH-Analogues 2005; abstract 59
  • 48 Uemura T, Shirasu K, Katagiri N. et al . Low-dose GnRH agonist therapy for the management of endometriosis.  J Obstet Gynaecol Res. 1999;  25 295-301
  • 49 Uemura T, Yoshikata H, Ishikawa M. et al .Effects of pre-treatment with GnRH-Agonists on bone mineral density in patients with endometriosis. 5th International Symposium on GnRH-Analogues 1999; abstract 45
  • 50 Vercellini P, Crosignani P G, Fadini R. et al . A gonadotropin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis.  Br J Obstet Gynaecol. 1999;  106 672-677
  • 51 Waller K G, Shaw R W. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up.  Fertil Steril. 1993;  59 511-515
  • 52 Zeitoun K M, Bulun S E. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target.  Fertil Steril. 1999;  72 961-969
  • 53 Zupi E, Marconi D, Sbracia M. et al . Add-back therapy in the treatment of endometriosis-associated pain.  Fertil Steril. 2004;  82 1303-1308

Univ. Prof. Dr. K. W. Schweppe

Frauenklinik der Ammerland Klinik GmbH · Akademisches Lehrkrankenhaus der Universität Göttingen

Lange Straße 38

26655 Westerstede

Deutschland

Phone: +49/44 88/50 32 30

Fax: +49/44 88/50 39 99

Email: schweppe@ammerland-klinik.de

    >